Bookmark Saya

DOAJ Open Access 2022

PB2099: A FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-1607, A FIRST-IN-CLASS ORAL CBL-B INHIBITOR, IN PATIENTS WITH ADVANCED MALIGNANCIES INCLUDING RICHTER TRANSFORMATION DLBCL

A. Sharp A. Williams S. Blagden R. Plummer D. Hochhauser +10 lainnya
Lihat Sumber DOI

Topik & Kata Kunci

Diseases of the blood and blood-forming organs

Penulis (15)

A

A. Sharp

A

A. Williams

S

S. Blagden

R

R. Plummer

D

D. Hochhauser

M

M. G. Krebs

S

S. Pacey

J

J. Evans

S

S. Whelan

S

S. Nandakumar

S

S. Rogers

K

K. L. Jameson

F

F. G. Basile

J

J. de Bono

H

H.-T. Arkenau

Format Sitasi

APA MLA BibTeX
Sharp, A., Williams, A., Blagden, S., Plummer, R., Hochhauser, D., Krebs, M.G. et al. (2022). PB2099: A FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-1607, A FIRST-IN-CLASS ORAL CBL-B INHIBITOR, IN PATIENTS WITH ADVANCED MALIGNANCIES INCLUDING RICHTER TRANSFORMATION DLBCL. https://doi.org/10.1097/01.HS9.0000851228.41662.2b

Akses Cepat

PDF tidak tersedia langsung

Cek di sumber asli →
Lihat di Sumber doi.org/10.1097/01.HS9.0000851228.41662.2b
Informasi Jurnal
Tahun Terbit
2022
Sumber Database
DOAJ
DOI
10.1097/01.HS9.0000851228.41662.2b
Akses
Open Access ✓